scholarly journals Bone Mineral Density in Children and Adolescents With Prader-Willi Syndrome: A Longitudinal Study During Puberty and 9 Years of Growth Hormone Treatment

2015 ◽  
Vol 100 (4) ◽  
pp. 1609-1618 ◽  
Author(s):  
N. E. Bakker ◽  
R. J. Kuppens ◽  
E. P. C. Siemensma ◽  
R. F. A. Tummers-de Lind van Wijngaarden ◽  
D. A. M. Festen ◽  
...  
Keyword(s):  
Bone Mineral Density ◽  
Growth Hormone ◽  
Longitudinal Study ◽  
Children And Adolescents ◽  
Bone Mineral ◽  
Growth Hormone Treatment ◽  
Hormone Treatment ◽  
Prader Willi Syndrome ◽  
Mineral Density

Growth hormone treatment and bone mineral density in pediatric patients with Prader–Willi syndrome

2021 ◽  
Vol 0 (0) ◽  
Author(s):  
Yuji Oto ◽  
Nobuyuki Murakami ◽  
Takeshi Inoue ◽  
Keiko Matsubara ◽  
Sohei Saima ◽  
...  
Keyword(s):  
Bone Mineral Density ◽  
Growth Hormone ◽  
Bone Mineral ◽  
Pediatric Patients ◽  
Standard Deviation Score ◽  
Hormone Treatment ◽  
Prader Willi Syndrome ◽  
Mineral Density ◽  
Gh Treatment ◽  
Total Body

Abstract Objectives Previous reports indicate that growth hormone (GH) treatment for Prader–Willi syndrome (PWS) improves bone mineral density (BMD) only when initiated at a young age and not when initiated in adulthood. However, there are no data on BMD during long-term GH treatment of Japanese children and adolescents with PWS. Thus, this study aimed to investigate BMD changes among patients with PWS, who were undergoing GH treatment from childhood to adolescence. Methods Sixty-seven pediatric patients with PWS who had GH treatment initiated during childhood between January 2003 and June 2020 were evaluated. To avoid underestimation, we used total body BMD, which was evaluated using dual-X-ray absorptiometry adjusted for the BMD z-score using patient height, sex, and age. Results In both sexes, age was negatively correlated with the BMD-standard deviation score (SDS) (male: r=−0.156 [p=0.042]; female: r=−0.197 [p=0.043]), which started to decrease in childhood. Conclusions The BMD-SDS of patients with PWS decreases gradually despite GH treatment. As there are no clear recommendations about monitoring of bone health in patients with PWS, further studies are needed to improve the guidelines for screening of BMD and treatment of patients with PWS.

Changes in Bone Mineral Density, Growth Velocity and Renal Function of Prepubertal Uremic Children during Growth Hormone Treatment

1996 ◽  
Vol 46 (6) ◽  
pp. 263-268 ◽  
Author(s):  
Roberto Lanes ◽  
Peter Gunczler ◽  
Nelson Orta ◽  
Milagros Bosquez ◽  
Rafael Scovino ◽  
...  
Keyword(s):  
Bone Mineral Density ◽  
Growth Hormone ◽  
Renal Function ◽  
Bone Mineral ◽  
Growth Velocity ◽  
Growth Hormone Treatment ◽  
Hormone Treatment ◽  
Mineral Density ◽  
Density Growth
Sign in / Sign up

Export Citation Format

Share Document